Clinical Trials Logo

Head and Neck Cancers clinical trials

View clinical trials related to Head and Neck Cancers.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05122221 Recruiting - Cervical Cancer Clinical Trials

CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers

Start date: July 17, 2022
Phase: Phase 1
Study type: Interventional

A single center, open, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of CRTE7A2-01 TCR-T cell for HPV16 positive advanced cervical, anal, or head and neck cancers. The study will determine MTD of CRTE7A2-01 TCR-T cell injection, as well as investigate RP2D.

NCT ID: NCT04565457 Recruiting - Prostate Cancer Clinical Trials

A Pilot Study Evaluating the Effect of 2D Antiscatter Grids on CBCT Image Quality

Start date: April 21, 2023
Phase: N/A
Study type: Interventional

This is Pilot study that investigates the CBCT(Cone beam computed tomography) image quality improvement provided by the 2D antiscatter grid technology. The primary objective is to assess the improvement in tissue visualization in an observer study, which will be conducted in a blinded fashion.

NCT ID: NCT02997332 Recruiting - Clinical trials for Head and Neck Cancers

Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma

MEDINDUCTION
Start date: March 30, 2017
Phase: Phase 1
Study type: Interventional

The prognosis of patients with locally advanced SCCHN is poor. Results of recent randomized trials evaluating induction chemotherapy by docetaxel, cisplatin, 5 fluorouracil are conflicting, and benefit on overall survival is uncertain. Improve efficacy of induction chemotherapy is important without increase toxicities. Durvalumab is a promising agent in SSCHN. The safety of combination of docetaxel, cisplatin, 5 fluorouracil with durvalumab is unknown. The aim of the study is to evaluate the feasibility and the safety of the association of DCF (standard regimen for induction in SSCCHN) and durvalumab. The safety profile of DCF and durvalumab are different, so the expected toxicities should not be additive. The addition of durvalumab to DCF could improve the efficacy of induction chemotherapy and the prognostic of patients with SSCCHN. Concerning the translational research, the aim will be to explore the relationships between immune capacity, specificity, activation state and clinical outcome to help elucidate the determinants of response to immunotherapy.

NCT ID: NCT00568490 Recruiting - Lung Cancer Clinical Trials

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

Start date: September 1, 1998
Phase:
Study type: Observational

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.